July 2026 brought a dense run of FDA activity across breast, lung, bladder, and blood cancers, along with a pancreatic cancer application that moved through review in a matter of weeks. Four new approvals landed in the space of 2 weeks in the middle of the month, a formulation switch gave patients with multiple myeloma a needle-and-syringe alternative to infusion chairs, and a liver cancer combination hit a regulatory wall for the third time. Meanwhile, an oncolytic virus therapy for melanoma that has already collected two rejections heads into an advisory committee meeting this week, setting up one of the more closely watched decisions of the summer. Here is a roundup of the most notable FDA oncology news from July 2026.
